Mucuna pruriens: what studies say and why it is banned in supplements
Mucuna pruriens contains levodopa and from April 4, 2024, it is prohibited to use it in dietary supplements in Poland. What studies have shown and what are the real interactions.
Mucuna pruriens, or velvet bean, is a legume whose seeds contain levodopa, the active substance in medications used for Parkinson’s disease. It is not an ordinary adaptogen, and this is not a matter of opinion: from April 4, 2024, mucuna is among the plant materials that cannot be used in the production of dietary supplements in Poland. A layer of claims has grown around this plant that do not withstand verification at the source: dosing schemes without basis, cyclic protocols that no one has studied, and numbers attributed to studies where they do not exist. This text explains the origin of the Polish ban and where we read it, what two studies involving patients really showed, how interactions with medications work, and under what symptoms one should discontinue use and contact a doctor.
KEY INFORMATION
• Mucuna pruriens (velvet bean) is listed in the register of substances and plant materials prohibited for use in dietary supplements, maintained by the Chief Sanitary Inspectorate.
• Basis: regulation of the Minister of Health from March 13, 2024, regarding substances enriching food (Journal of Laws 2024 item 420), effective from April 4, 2024.
• The seeds contain 4 to 7 percent levodopa, which is the active substance of medicinal products, not a compound with solely nutritional effects.
• Simultaneous use of levodopa and a non-selective MAO inhibitor is contraindicated due to the risk of hypertensive crisis.
• Alarm symptoms: involuntary movements, palpitations, hallucinations or severe disorientation, fainting upon standing. Discontinue use and contact a doctor.
• Clinical studies concerned patients with Parkinson’s disease under the supervision of a neurologist, not healthy individuals seeking mood improvement.
Is mucuna allowed in dietary supplements in Poland?
No, it is not allowed. Mucuna pruriens is listed in the register of substances and plant materials prohibited for use in dietary supplements, maintained by the Chief Sanitary Inspectorate, alongside, among others, yohimbine, methysticin, and pancreatin. The basis is the regulation of the Minister of Health from March 13, 2024, regarding substances enriching food, published on March 20, 2024, as Journal of Laws 2024 item 420 and effective from April 4, 2024. We verified the status of the act as effective in the register of the Electronic Journal of Laws.
The reason for such a decision stems directly from the chemistry of the seeds. Levodopa is the active substance of registered medicinal products used in Parkinson’s disease and is subject to medical supervision, dose control, and monitoring of adverse effects. A plant material with variable content of this substance does not provide any of these guarantees. In a review published in the Journal of Traditional and Complementary Medicine, the authors report the levodopa content in seeds at 4 to 7 percent and list it among the toxic compounds of raw material (Lampariello et al., J Tradit Complement Med 2012, PMC3942911).
It is worth noting what this ban does not mean. It is not a statement that levodopa does not work, because it does work and is a drug with proven efficacy. It is a statement that this substance is not sold as a dietary supplement, where no one controls either the dose or the qualifications of the person reaching for the preparation.
How does mucuna pruriens affect dopamine?
Levodopa from the seeds is absorbed in the small intestine by neutral amino acid transporters and crosses the blood-brain barrier, which dopamine itself cannot do. In the brain, aromatic amino acid decarboxylase converts it into dopamine. This is the same mechanism that Parkinson’s medications rely on, and that is why mucuna does not behave like a calming or toning herb.
An important difference concerns what is not present in the seeds. Medicinal preparations combine levodopa with a peripheral decarboxylase inhibitor, benserazide or carbidopa, so that levodopa does not convert into dopamine before reaching the brain. The seeds do not contain such an addition, so a larger portion of the substance converts peripherally. The result is nausea, vomiting, and fluctuations in blood pressure, as well as less predictability of the effect.
A lot of claims have grown around the composition of the seeds that have no support in the cited literature. The aforementioned review does not mention serotonin, 5-HTP, nicotine, or beta-carbolines in the seeds. It does mention tetrahydroisoquinolines and tryptamines with hallucinogenic effects like Mucuna. Similarly, it does not mention any influence on growth hormone or Leydig cells, which are sometimes cited to explain the alleged effect on testosterone.
What did studies on patients with Parkinson’s disease show?
Two randomized, blinded studies with a crossover design tested mucuna in patients with Parkinson’s disease. Both involved patients under the care of a neurologist and both studied single doses, not long-term supplementation. The results are favorable for mucuna in terms of speed of action and tolerance, but say nothing about healthy individuals.
| Study | Who and how many | What was given | Result |
|---|---|---|---|
| Katzenschlager et al., J Neurol Neurosurg Psychiatry 2004 | 8 patients with Parkinson’s disease and short response to levodopa | Single doses: levodopa with carbidopa or 15 g or 30 g of seed preparation, at weekly intervals | At 30 g, onset of action after 34.6 instead of 68.5 minutes; ON state duration longer by 21.9 percent, or 37 minutes. No significant differences in dyskinesias and tolerance |
| Cilia et al., Neurology 2017 (NCT02680977) | 18 patients with advanced Parkinson’s disease | Six single doses in random order, including roasted seed powder 12.5 and 17.5 mg/kg and placebo | Higher dose provided greater motor improvement after 90 and 180 minutes, longer ON state, fewer dyskinesias, and fewer adverse events than the reference drug. No differences in circulatory response |
| Shukla et al., Fertility and Sterility 2009 | 75 healthy fertile men as a control group and 75 men diagnosed with infertility | Treatment with seed preparation; measurement of hormones by radioimmunoassay, catecholamines by HPLC | Increase in testosterone, LH, dopamine, adrenaline, and noradrenaline; decrease in FSH and prolactin; improvement in sperm count and motility |
Two things in this table are often misrepresented. In the 2004 study, the comparative time to onset of action was 68.5 minutes, not 55, and the authors explicitly stated that they found no significant differences in the severity of dyskinesias (Katzenschlager et al. 2004, PMC1738871). A lesser severity of dyskinesias was only shown in the 2017 study, with a single dose (Cilia et al., Neurology 2017, PMC5539737). Attributing this result to the 2004 work is a mistake.
What is known about the effect of mucuna on male fertility?
A study published in Fertility and Sterility included 75 healthy fertile men as a reference group and 75 men diagnosed with infertility. In infertile men, a reduced sperm count and motility, as well as lower levels of testosterone, luteinizing hormone, dopamine, adrenaline, and noradrenaline were found. After treatment with the seed preparation, these values increased, while FSH and prolactin levels decreased (Shukla et al., Fertility and Sterility 2009, PMID 18973898).
This work is sometimes cited under the name Ahmad and from the year 2008, with numbers stating an increase in sperm motility by 37 percent and a decrease in cortisol by 28 percent in men with stress-related infertility. None of these values are included in the summary of the work, nor is there any measurement of cortisol or specification of the duration of therapy. They could not be confirmed in the available summary, so presenting them as a result of this study has no basis.
It should also be noted who the study concerned. The participants were men with diagnosed infertility, not healthy men wanting to increase testosterone. The results obtained in the group with the disorder do not automatically transfer to individuals without this disorder.
Who should avoid mucuna and when to seek help?
Discontinue use and contact a doctor if involuntary body movements, accelerated or irregular heartbeat, hallucinations or severe disorientation occur, as well as fainting or dizziness upon standing, which indicate a drop in blood pressure. Nausea and vomiting, especially on an empty stomach, are the most common symptoms of peripheral conversion of levodopa into dopamine.
The interaction with the most serious consequences concerns monoamine oxidase inhibitors, but requires differentiation. The product characteristics of medicinal products containing levodopa with benserazide indicate as a contraindication treatment with non-selective MAO inhibitors, due to the risk of hypertensive crisis, and require a break of at least two weeks after such treatment. Selective MAO-B inhibitors, such as selegiline and rasagiline, and the selective MAO-A inhibitor moclobemide are not contraindicated separately, but their simultaneous use corresponds to non-selective inhibition and is unacceptable.
Two groups should be mentioned separately. Individuals treated for Parkinson’s disease should not add levodopa from another source without the knowledge of their neurologist, as it adds to the dose of the medication. Individuals diagnosed with psychosis or bipolar affective disorder, as well as those with such a diagnosis in their family history, should discuss the matter with a psychiatrist, as increased dopaminergic transmission may worsen symptoms. This text does not provide any doses or dosing schemes, as mucuna is not an allowed ingredient in dietary supplements in Poland, and levodopa as a medicinal substance requires medical supervision.
Frequently asked questions
Is mucuna pruriens allowed in dietary supplements in Poland?
No. Mucuna pruriens is listed in the register of substances and plant materials prohibited for use in dietary supplements, maintained by the Chief Sanitary Inspectorate. The basis is the regulation of the Minister of Health from March 13, 2024, Journal of Laws 2024 item 420, effective from April 4, 2024.
Does mucuna really increase dopamine levels?
The levodopa contained in the seeds crosses the blood-brain barrier and is converted into dopamine by aromatic amino acid decarboxylase. This is a pharmacological mechanism, the same one that Parkinson’s medications rely on. However, clinical studies evaluated motor response in patients, not mood in healthy individuals.
Does mucuna work better than Parkinson’s disease medication?
In two studies with a single dose in patients, mucuna acted faster and longer than the reference preparation. Neither evaluated long-term use or compared effectiveness in chronic therapy. The authors of the 2004 study explicitly stated that a long-term assessment is still needed.
What symptoms indicate that use should be discontinued?
Involuntary body movements, accelerated or irregular heartbeat, hallucinations or severe disorientation, and fainting upon standing. Persistent nausea and vomiting also require consultation. Each of these symptoms is an indication to discontinue use and contact a doctor, not to change the timing of intake.
What medications does mucuna interact with and in which direction?
With non-selective MAO inhibitors, there is a risk of hypertensive crisis, and this is a contraindication. It acts oppositely with antipsychotic medications, so both sides lose effectiveness. In individuals treated with levodopa, it adds to the dose of the medication. Blood pressure-lowering medications may exacerbate drops in blood pressure.
Can mucuna be combined with ashwagandha?
We did not find a study that tested this combination in humans, so the answer is: unknown. The lack of described interaction is not evidence of its absence, just a lack of data. Since mucuna is not an allowed ingredient in dietary supplements in Poland, the question of combining it with anything loses practical significance.
If you are looking for plant ingredients studied for mood and neurotransmission, we have separately described 5-HTP as a serotonin precursor and ashwagandha in the context of male fertility, where the data comes from randomized studies.
This article is for informational and educational purposes and does not replace consultation with a doctor. If you are pregnant, breastfeeding, taking medications, or have chronic conditions, consult the use of supplements or herbs with a specialist.
Author: Michał Waluk · Published: 2026-07-08 · Updated: 2026-08-16
